Goldman reinstates buy rating on 4D Molecular, cites upcoming catalysts (NASDAQ:FDMT)

Goldman Sachs has reinstated its buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT), citing upcoming catalysts.

The investment bank said it sees shares trading higheron catalysts that include 24-week data for 4D-150 in wet AMD and diabetic macular edema in 2H, FDA

Source link

Related Articles

Back to top button